Last reviewed · How we verify
Standard dose rifampicin
Rifampicin inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase.
Rifampicin inhibits bacterial RNA synthesis by binding to the beta subunit of bacterial RNA polymerase. Used for Tuberculosis, Prophylaxis of Mycobacterium tuberculosis infection.
At a glance
| Generic name | Standard dose rifampicin |
|---|---|
| Also known as | RIF10 |
| Sponsor | Radboud University Medical Center |
| Drug class | Bacterial RNA polymerase inhibitor |
| Target | beta subunit of bacterial RNA polymerase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
This inhibition prevents the transcription of essential bacterial genes, ultimately leading to the death of the bacteria. Rifampicin is a broad-spectrum antibiotic that is effective against a wide range of bacteria, including Mycobacterium tuberculosis.
Approved indications
- Tuberculosis
- Prophylaxis of Mycobacterium tuberculosis infection
Common side effects
- Hepatotoxicity
- Thrombocytopenia
- Flu-like symptoms
Key clinical trials
- Safety and Tolerability of Metformin in People With Tuberculosis (TB) and Human Immunodeficiency Virus (HIV) (PHASE2)
- Shortened Regimen for Drug-susceptible TB in Children (PHASE3)
- Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis (PHASE2)
- AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT (PHASE2)
- Drug Interaction and Food Effect Study of CS0159 (PHASE1)
- Ultra-Short Course Bedaquiline, Clofazimine, Pyrazinamide and Delamanid Versus Standard Therapy for Drug-Susceptible TB (PHASE2)
- Asymptomatic TB With Innovative Modified Short-course Regimens (PHASE4)
- Shorter and Safer Treatment Regimens for Latent TB (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard dose rifampicin CI brief — competitive landscape report
- Standard dose rifampicin updates RSS · CI watch RSS
- Radboud University Medical Center portfolio CI